Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
October 21, 2015 at 10:00 AM EDT
[Business Wire] – Gilead Sciences, Inc. today confirmed that the company fulfilled a request for compassionate access to GS-5734, a novel nucleotide analogue in development for the potential treatment of Ebola Virus Disease . . . → Read More: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015 Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment